DocGo Showcases Strategic Growth in Mobile Health at Cantor Global Healthcare Conference
New York, NY, September 3, 2025 — DocGo Inc. (NASDAQ: DCGO), a leading provider of technology-enabled mobile health and medical transportation services, presented its ambitious growth strategy at the Cantor Global Healthcare Conference on Wednesday, September 3, 2025. Led by CEO Lee Bienstock, the fireside chat highlighted the company’s transformation into a comprehensive mobile health provider, emphasizing integration with hospital systems, expansion in medical transportation, and a pivot toward long-term government contracts.
A Transformative Vision
DocGo’s presentation underscored its mission to deliver healthcare “at any address,” leveraging proprietary technology and a dedicated field staff of over 5,000 certified health professionals. The company is moving away from episodic emergency care contracts, such as those tied to migrant programs, to focus on sustainable, recurring revenue streams. Bienstock highlighted the completion of DocGo’s integration with Epic systems, which enhances logistics efficiency by allowing hospital staff to track ambulance arrivals in real time, streamlining patient transfers.
“We’ve made incredible progress over the last two years,” Bienstock said. “Our deep integration with health systems and our technology backbone position us to meet the growing demand for care outside traditional hospital settings.”
Growth Projections and Key Segments
DocGo projected a 15% annual growth rate for its medical transportation business, which constitutes the majority of its health systems revenue, expected to reach $250 million in 2025. The company’s Care in the Home segment, encompassing mobile health services like in-home diagnostics and primary care, is anticipated to grow by an impressive 50% to 100% year-over-year. This growth is driven by initiatives like care gap closure programs, with over 700,000 patients enrolled by late 2024 and a Net Promoter Score of 86, signaling strong demand.
The company is also expanding its mobile phlebotomy services following the 2024 acquisition of PTI Health, enhancing its ability to offer integrated care. Strategic partnerships, such as $3.4 million in Veterans Affairs (VA) contracts and public health initiatives, further bolster DocGo’s position in underserved regions.
Navigating Challenges
Despite its optimistic outlook, DocGo acknowledged challenges in transitioning from high-margin, non-recurring contracts, particularly migrant-related programs, which are expected to generate $50 million in 2025, primarily in the first half. The wind-down of these programs contributed to a revenue decline to $616.6 million in 2024 from $624 million in 2023, though net income rose to $13.4 million, reflecting improved cost discipline and higher margins in core services.
Bienstock addressed the competitive landscape, noting rivals like Teladoc and Amwell but emphasizing DocGo’s unique infrastructure and service breadth as key differentiators. The company’s strong balance sheet, with $128.7 million in cash reserves and $150 million in receivable collection targets for 2025, provides a cushion for investments in technology and geographic expansion.
Strategic Investor Engagement
DocGo’s appearance at the Cantor Conference is part of a broader 2025 investor outreach strategy, including presentations at the Three Part Advisors Midwest Conference and Morgan Stanley’s 23rd Annual Global Healthcare Conference. These engagements aim to reframe DocGo’s narrative in the mobile health sector, highlighting its operational restructuring and growth potential in a $100 billion U.S. market projected to grow at 8.5% annually through 2030.
Looking Ahead
With a focus on value-based care and government partnerships, DocGo is positioning itself as a leader in the evolving mobile health landscape. The company plans to transition to risk-based contracts by 2026 or 2027, starting with fee-for-service models, to drive recurring revenue. However, its conservative 2025 revenue guidance of $410–$450 million, down nearly 30% from 2023, reflects the short-term impact of phasing out volatile contracts.
Investors responded positively, with DocGo’s stock showing modest gains in pre-market trading following the presentation. As the company continues to innovate and expand, its ability to execute on long-term contracts and maintain operational agility will be critical to sustaining growth in a competitive market.
For more information, contact DocGo Investor Relations at ir@docgo.com or visit www.docgo.com.